Ocugen

Edit info

Founded: 2013

Location: Malvern, PA

Employee range: 1-50

Clinical stage: Clin3

Therapy area: Knee cartilage defects

Drug types: BON, INF, VAC, OPH, GEN, GER

Lead product: Neocart

Funding: 100-500M

ocugen.com

linkedin.com

job board

Drug notes:

OCU400 Clin3 inherired retinal diseases (ODD); OCU410 Clin1/Clin2 dry AMD; OCU410ST Clin1/Clin2 Stargardt; OCU200 Clin0 DME, diabetic retinopathy, wet AMD; OCU500 Clin0 COVID-19; OCU510 Clin0 flu; OCU520 Clin0 COVID-19/flu

About:

Ocugen is involved with the discovery and development of therapies to cure retinal diseases as well as protect against COVID-19. Core to Ocugen’s approach is delivering innovative options for patients, whether it be for unmet clinical needs or providing choice in the area of vaccines. Using their breakthrough modifier gene therapy platform, Ocugen is advancing vaccine research, as well as gene and cell therapies. Currently, Ocugen has several assets in clinical trials, with their lead cell therapy candidate, Neocart® in Phase 3 clinical trials for the treatment of articular cartilage defects in the knee.